IUPAC/Chemical Name
(E)-N-(2-(Diphenylmethoxy)-ethyl)-N-methylcinnamylamine
InChi Key
QTKQVDXGCWKEHE-SDNWHVSQSA-N
InChi Code
InChI=1S/C25H27NO/c1-26(19-11-14-22-12-5-2-6-13-22)20-21-27-25(23-15-7-3-8-16-23)24-17-9-4-10-18-24/h2-18,25H,19-21H2,1H3/b14-11+
SMILES Code
CN(CCOC(C1=CC=CC=C1)C2=CC=CC=C2)C/C=C/C3=CC=CC=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
357.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Mohiuddin SM, Hee TT, Hunter CB, Hilleman DE, Sketch MH Sr. Loss of efficacy during long-term cifenline therapy: development of antiarrhythmic resistance? Ann Pharmacother. 1993 May;27(5):550-4. doi: 10.1177/106002809302700502. PMID: 8347900.
2: Massarella JW, Defeo TM, Liguori J, Passe S, Aogaichi K. The effects of cimetidine and ranitidine on the pharmacokinetics of cifenline. Br J Clin Pharmacol. 1991 Apr;31(4):481-3. doi: 10.1111/j.1365-2125.1991.tb05566.x. PMID: 2049259; PMCID: PMC1368338.
3: Aoyama N, Sasaki T, Yoshida M, Suzuki K, Matsuyama K, Aizaki T, Izumi T, Kondo R, Kamijo Y, Soma K, Ohwada T. Effect of charcoal hemoperfusion on clearance of cibenzoline succinate (cifenline) poisoning. J Toxicol Clin Toxicol. 1999;37(4):505-8. doi: 10.1081/clt-100102443. PMID: 10465249.
4: Kostis JB, Davis D, Kluger J, Aogaichi K, Smith M. Cifenline in the short- term treatment of patients with ventricular premature complexes: a double-blind placebo-controlled study. J Cardiovasc Pharmacol. 1989 Jul;14(1):88-95. doi: 10.1097/00005344-198907000-00016. PMID: 2475722.
5: Ross AJ, Go MV, Casey DL, Palling DJ. Kinetics and mechanism of the hydrolysis of a 2-substituted imidazoline, cibenzoline (cifenline). J Pharm Sci. 1987 Apr;76(4):306-9. doi: 10.1002/jps.2600760409. PMID: 3598889.
6: Nestico PF, Morganroth J, Horowitz LN. New antiarrhythmic drugs. Drugs. 1988 Mar;35(3):286-319. doi: 10.2165/00003495-198835030-00005. PMID: 3286214.
7: Touboul P. Cibenzoline [Cibenzoline]. Arch Mal Coeur Vaiss. 1985 Oct;78 Spec No:91-4. French. PMID: 3938265.
8: Nakagawa Y, Ishizaki M, Kozono A, Hanada K, Higashi T, Ueyama H. [A case of myasthenia-like symptoms induced by cibenzoline overdosage]. Rinsho Shinkeigaku. 2018 Jan 26;58(1):41-44. Japanese. doi: 10.5692/clinicalneurol.cn-001070. Epub 2017 Dec 22. PMID: 29269691.
9: Hamada M, Ikeda S, Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy. J Cardiol. 2014 Jul;64(1):1-10. doi: 10.1016/j.jjcc.2014.02.022. Epub 2014 Apr 13. Erratum in: J Cardiol. 2014 Oct;64(4):330. PMID: 24735741.
10: Omae T. [Perioperative management for patients with hypertrophic cardiomyopathy]. Masui. 2014 Jan;63(1):16-21. Japanese. PMID: 24558927.
